Instead, ongoing clinical trial studies are investigating EVs’ cargo, such as Aβ and tau proteins, for potential AD markers, due to their superior sensitivity, specificity, and accessibility in saliva, blood, and other body fluids [224,225]. The gene discussed is MAPT; the disease is Alzheimer disease.